| Returns | 1W : -9.6% , 1M : 35.1%,1Y : 332.7% |
| Peers & Returns | 1W | 1M | 1Y |
| KOPRAN | -9.6% | 35.1% | 332.7% |
| SUN PHARMACEUTICAL INDUSTRIES | -3.9% | -3.8% | 17.1% |
| DRREDDYS LABORATORIES | -1.5% | -3.5% | 80.5% |
| DIVIS LABORATORIES | 1.6% | 1.4% | 78.9% |
| CIPLA | 1% | -1.2% | 72.4% |
| PIRAMAL ENTERPRISES | -2.9% | -0.1% | -18.8% |
| LUPIN | -5.3% | -6.7% | 31% |
| AUROBINDO PHARMA | -0.8% | -3.2% | 69.4% |
| TORRENT PHARMACEUTICALS | -6.2% | -5.5% | 47.2% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S PEG |
39.35 2.34 2.59 107.58 |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
244% 145% 282% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For Banking industry, Good = Ratio less than 13 Average = Ratio between 13 and 15 Bad = Ratio greater than 15 For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.2 0.23 0.25 0.23 |
0.47 0.58 0.61 0.55 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0 % |
|---|---|
| As of : July 14,2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Parameter | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
-17.75% 16.87% 24.66% 24.39% |
-2.51% 124.71% 204.85% 207.77% |
| QtrlyTrend |
4
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
